Table 1 Characteristics of studies included in this systematic review
Studies | Study design | Location/setting | No. patients (intervention/control) | Age, years (intervention/control) | Treatment of intervention group | Treatment of control group | Follow-up, months |
|---|---|---|---|---|---|---|---|
Li [10] | Open-label RCT | Hong Kong/single center | 30/30 | 58.0/59.1 | Ramipril 5 mg/day | Conventional antihypertensive therapy except for ACEI or ARB or both | 12 |
Phakdeekitcharoen [16] | Open-label cross-over RCT | Thailand/single center | 29 | 44.8 | Group 1: Enalapril 10 mg/day Group 2: Candesartan 8 mg/day | Group 1: Candesartan 8 mg/day Group 2: Enalapril 10 mg/day | 4 |
Reyes-Marín [20] | Parallel RCT | Mexico/single center | 30/30 | 42.5/49.2 | Group 1: Enalapril 10 mg/day | Group 2: Losartan 50 mg/day | 12 |
Suzuki [11] | Double-blind RCT | Japan/single center | 14/10 | 56/57 | Valsartan 40~80 mg/day | Conventional antihypertensive therapy | 12 |
Suzuki [15] | Open-label RCT | Japan/single center | 18/16 | 63.5/63.5 | Valsartan 40~80 mg/day | Conventional antihypertensive therapy except for ACEI or ARB or both | 24 |
Shigenaga [19] | Open-label RCT | Japan/single center | 15/15 | 52.9/53.3 | Group 1: Candesartan l~4 mg/day Group 2: Valsartan ~ 40 mg/day | Conventional antihypertensive therapy except for ACEI or ARB or both | 6 |
Zhong [18] | Open-label RCT | China/single center | 24/20 | 44 | Irbesartan 300 mg/day | Conventional antihypertensive therapy except for ACEI or ARB or both | 12 |
Wang [17] | Open-label RCT | China/single center | 19/13 | 42 | Valsartan 80 mg/day | Conventional antihypertensive therapy except for ACEI or ARB or both | 28 |